Lee's Pharmaceutical Holdings Ltd (0950.HK)
5.78HKD
20 May 2019
HK$-0.18 (-3.02%)
HK$5.96
HK$6.00
HK$6.12
HK$5.78
235,500
498,805
HK$12.90
HK$5.29
Latest Key Developments (Source: Significant Developments)
Lee's Pharmaceutical Holdings Recommends Payment Of Final Dividend Of Hk8.4 Cents Per Share
March 28 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>::RECOMMENDS PAYMENT OF FINAL DIVIDEND OF HK8.4 CENTS PER SHARE.FY PROFIT ATTRIBUTABLE HK$418.3 MILLION VERSUS HK$232.6 MILLION.FY REVENUE HK$1.14 BILLION VERSUS HK$1.01 BILLION. Full Article
Lee's Pharmaceutical Says China Oncology Focus Entered Licensing Agreement With Auransa
Dec 20 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>::CHINA ONCOLOGY FOCUS ENTERED LICENSING AGREEMENT GRANTING COF EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALISE AU018 IN CHINA.LICENSING AGREEMENT ENTERED WITH AURANSA, INC.COF ALSO GRANTED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALISE AU018 IN OTHER COUNTRIES OF SOUTHEAST ASIA. Full Article
Auransa Enters Exclusive Licensing Agreement With China Oncology Focus Limited
Dec 19 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>::AURANSA ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH CHINA ONCOLOGY FOCUS LIMITED, AN AFFILIATE OF LEE’S PHARMACEUTICAL HOLDINGS, FOR RIGHTS TO AU018 IN GREATER CHINA AND SOUTHEAST ASIA.AURANSA ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH CHINA ONCOLOGY FOCUS LIMITED, AN AFFILIATE OF LEE’S PHARMACEUTICAL HOLDINGS, FOR RIGHTS TO AU018 IN GREATER CHINA AND SOUTHEAST ASIA.AURANSA - AURANSA IS ELIGIBLE TO RECEIVE UP TO $22.5 MILLION UPON SUCCESSFUL ATTAINMENT OF KEY MILESTONES.AURANSA - WILL RECEIVE AN UPFRONT PAYMENT, POTENTIAL FUTURE MILESTONE PAYMENTS AND HIGH SINGLE DIGIT ROYALTIES ON FUTURE NET SALES.AURANSA - COF WILL BE RESPONSIBLE FOR FUNDING AND CONDUCTING ALL REMAINING PRECLINICAL AND CLINICAL ACTIVITIES.AURANSA - COMPANY WILL RETAIN RIGHTS TO AU018 FOR ALL MARKETS OUTSIDE SCOPE OF THIS AGREEMENT.AURANSA - WILL HAVE RIGHTS TO ACCESS AND USE ANY AU018 DATA GENERATED BY COF AS PART OF ITS DEVELOPMENT AND COMMERCIALIZATION EFFORTS. Full Article
Lee's Pharmaceutical Holdings Says Unit To Advance Shareholder Loan In Principal Amount Hk$3 Mln
Sept 28 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>::UNIT TO ADVANCE SHAREHOLDER LOAN IN PRINCIPAL AMOUNT OF HK$3 MILLION TO POWDER PHARMACEUTICALS INCORPORATED. Full Article
Lee's Pharmaceutical Holdings Posts Qtrly Profit Attributable Of HK$55.6 Mln
Aug 30 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>::QTRLY PROFIT ATTRIBUTABLE HK$55.6 MILLION VERSUS HK$78.7 MILLION.QTRLY REVENUE HK$285.8 MILLION VERSUS HK$248.6 MILLION.DECLARED INTERIM DIVIDEND HK$0.034 PER SHARE. Full Article
Lee's Pharmaceutical Says FY Profit Attributable HK$232.6 Million
March 22 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>::FY REVENUE HK$1.01 BILLION, UP 8.5 PERCENT.FINAL DIVIDEND OF HK7.0 CENTS PER ORDINARY SHARE.FY PROFIT ATTRIBUTABLE HK$232.6 MILLION VERSUS HK$252.0 MILLION. Full Article
Lee's Pharmaceutical Holdings says qtrly profit attributable HK$61.8 mln
Nov 23 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>:Qtrly profit attributable to owners of company HK$61.8 million versus HK$72.8 million.Qtrly revenue HK$275.0 million versus HK$248.9 million a year ago. Full Article
Lee's Pharmaceutical Holdings says interim dividend hk$0.034 per ordinary share
Aug 24 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>:Interim dividend declared hk$0.034 per ordinary share.Hy revenue 248.6 million versus hk$224.2 million.Hy profit attributable hk$78.690 million versus hk$68.311 million. Full Article
Lee's Pharmaceutical reports qtrly profit attributable HK$46.4 mln
May 31 (Reuters) - Lee's Pharmaceutical Holdings Ltd <0950.HK>:Qtrly revenue HK$226.2 million versus HK$225.5 million.Qtrly profit attributable to owners of company HK$46.4 million versus HK$53.1 million.Board does not recommend payment of dividend for three months ended 31 March 2017. Full Article
Earnings vs. 
Estimates